Crinetics Pharmaceuticals' (CRNX) "Buy" Rating Reaffirmed at

HC Wainwright reissued their buy rating on shares of Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) in a research note issued to investors on Thursday, Benzinga reports. The firm currently has a $60.00 price target on the stock. A number of other equities analysts also recently weighed in on the company. JMP Securities reiterated a market […]

Related Keywords

Stephenf Betz , Robertw Baird , Piper Sandler , Marc Wilson , Analyst Recommendations For Crinetics Pharmaceuticals , Alps Advisors Inc , Crinetics Pharmaceuticals Company Profile , News Ratings For Crinetics Pharmaceuticals Daily , Crinetics Pharmaceuticals Price Performance , Hennion Walsh Asset Management Inc , Comerica Bank , Securities Exchange Commission , Crinetics Pharmaceuticals , Citigroup , Cantor Fitzgerald , Crinetics Pharmaceuticals Inc , Free Report , Moderate Buy , Get Free Report , Exchange Commission , Walsh Asset Management , Crinetics Pharmaceuticals Daily ,